Corrigendum to “Nivolumab plus ipilimumab in melanoma patients with asymptomatic brain metastases: 7-year outcomes and quality of life from the multicenter phase III NIBIT-M2 trial” [Eur J Cancer 199 (2024) 113531]
Titel:
Corrigendum to “Nivolumab plus ipilimumab in melanoma patients with asymptomatic brain metastases: 7-year outcomes and quality of life from the multicenter phase III NIBIT-M2 trial” [Eur J Cancer 199 (2024) 113531]
Auteur:
Di Giacomo, Anna Maria Chiarion-Sileni, Vanna Del Vecchio, Michele Ferrucci, Pier Francesco Guida, Michele Quaglino, Pietro Guidoboni, Massimo Marchetti, Paolo Simonetti, Elena Santangelo, Federica Amato, Giovanni Covre, Alessia Camerini, Roberto Valente, Monica Mandalà, Mario Giannarelli, Diana Calabrò, Luana Maio, Michele